Lunai Bioworks(LNAI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LNAI Lunai Bioworks

Pre-Mkt 01-05 06:27:32 EST

0.9716

+0.0899

+10.20%

High0.9900	Low0.8613	Vol150.89K
Open0.9013	D1 Closing0.8817	Amplitude14.60%
Mkt Cap22.77M	Tradable Cap14.57M	Total Shares23.43M
T/O137.85K	T/O Rate1.01%	Tradable Shares15.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LNAI","market":"US","secType":"STK","nameCN":"Lunai Bioworks","latestPrice":0.9716,"timestamp":1767387600000,"preClose":0.8817,"halted":0,"volume":150891,"delay":0,"floatShares":15000000,"shares":23430653,"eps":-7.221734,"marketStatus":"Pre-Mkt","change":0.0899,"latestTime":"01-05 06:27:32 EST","open":0.9013,"high":0.99,"low":0.8613,"amount":137853.85916445,"amplitude":0.145968,"askPrice":0.9716,"askSize":15,"bidPrice":0.7957,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-7.221734,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1767623400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.9716,"postHourTrading":{"tag":"盘后","latestPrice":0.9716,"preClose":0.9716,"latestTime":"19:21 EST","volume":34,"amount":33.4133,"timestamp":1767399666311},"volumeRatio":0.9331185565169822,"impliedVol":1.4337,"impliedVolPercentile":0.6349},"requestUrl":"/m/hq/s/LNAI/wiki","defaultTab":"wiki","newsList":[{"id":"2590346916","title":"Lunai Bioworks Inc - Identifies Three Parkinson's Disease Subtypes","url":"https://stock-news.laohu8.com/highlight/detail?id=2590346916","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590346916?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:45","pubTimestamp":1765284336,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0HG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2590346910","title":"Lunai Bioworks Inc - Prioritized Drug Targets in $13 Bln Parkinson's Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2590346910","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590346910?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:45","pubTimestamp":1765284336,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0HG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2590634696","title":"Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritizes Drug Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2590634696","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590634696?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:45","pubTimestamp":1765284322,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc., an AI-powered biotechnology company, has announced the identification of three clinically relevant subtypes of Parkinson's disease and prioritized drug targets using its proprietary Augusta Platform. By integrating large-scale proteomic data from the Parkinson's Progression Markers Initiative with detailed clinical phenotyping, the company uncovered subtypes associated with rapid progression, cognitive decline, and functional impairment. These findings, recently highlighted in Science Times, aim to support the development of precision therapies and accelerate proof-of-concept programs. Lunai Bioworks is also exploring partnerships to apply these insights to ongoing drug development, co-develop biomarkers and companion diagnostics, and design smarter clinical trials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDLb1yhHv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2588046695","title":"BRIEF-Lunai Bioworks - Enters Sales Agreement With Dawson James Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046695","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046695?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:49","pubTimestamp":1764766172,"startTime":"0","endTime":"0","summary":"BRIEF-Lunai Bioworks - Enters Sales Agreement With Dawson James Securities - SEC FilingDec 3  - Lunai Bioworks Inc LNAI.O:LUNAI BIOWORKS INC - ENTERS SALES AGREEMENT WITH DAWSON JAMES SECURITIES - SEC FILINGLUNAI BIOWORKS INC - MAY OFFER & SELL STOCK UP TO $11.70 MILLION - SEC FILINGSource text: [ID:n0001731122-25-001625]Further company coverage: LNAI.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X815K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2588100250","title":"Lunai Bioworks Inc - May Offer & Sell Stock up to $11.70 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588100250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588100250?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:06","pubTimestamp":1764759993,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X815K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2586401146","title":"Lunai Bioworks Raises $3.1 Million in Private Placement of Shares and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2586401146","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586401146?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:49","pubTimestamp":1764107399,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. has announced a private placement with an accredited investor, selling 3,133,333 shares of its common stock at $1.00 per share, raising gross proceeds of $3,133,333. The agreement also includes the issuance of 1,044,444 three-year warrants, exercisable after 60 days. The securities were offered in reliance on exemptions from registration under the Securities Act, and are subject to resale restrictions. No underwriting discounts or commissions were paid in connection with the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL8q3QLd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"gpt_icon":0},{"id":"2586478744","title":"Lunai Bioworks Secures First Licensing LOI for Immune Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2586478744","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586478744?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:45","pubTimestamp":1764074718,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. announced it has secured its first Letter of Intent  to license its next-generation immune cell therapy platform. The agreement follows recent peer-reviewed publication of preclinical data showing complete regression of primary and metastatic pancreatic tumors in humanized models, with no recurrence observed. The company plans to advance the platform, known as Dendritic Cell Combination Therapy , toward scalable clinical applications for aggressive cancers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire  on November 25, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL9RRxcL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"gpt_icon":0},{"id":"2586478712","title":"Lunai Bioworks Secures First Licensing Loi Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2586478712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586478712?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:45","pubTimestamp":1764074700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nTUA7GVW6G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2583503655","title":"Lunai Bioworks Achieves Complete Regression of Both Primary and Metastatic Pancreatic Tumors in Preclinical Humanized Models, Marking a Breakthrough in Allogeneic Cancer Immunotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2583503655","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583503655?lang=en_us&edition=fundamental","pubTime":"2025-11-15 23:36","pubTimestamp":1763220993,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251115:nTUA61DRLD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LNAI","BK4139"],"gpt_icon":0},{"id":"2581241834","title":"Lunai Bioworks Announces Breakthrough Allogeneic Cell Therapy Reversing Pancreatic Tumors in Preclinical Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2581241834","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581241834?lang=en_us&edition=fundamental","pubTime":"2025-11-08 06:02","pubTimestamp":1762552928,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc., an AI-driven drug discovery and biodefense company, has announced a significant scientific development with the release of its second-generation allogeneic dendritic cell therapy platform. The results, published in the journal \"Vaccines,\" demonstrated that the company's next-generation immune cell therapy achieved complete regression of both primary and metastatic pancreatic tumors in preclinical humanized mouse models. According to Lunai Bioworks, these findings indicate that their vector optimization strategy retains therapeutic efficacy and advances the allogeneic dendritic cell  platform closer to IND-enabling studies. The full study, titled \"Modified Hematopoietic Stem Cell-Derived Dendritic Cell Therapy Retained Tumor-Inhibitory Function and Led to Regression of Primary and Metastatic Pancreatic Tumors in Humanized Mouse Models,\" is available in \"Vaccines.\" The results have already been presented through this publication.Disclaimer: This news brief was create","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL1Ys7h3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"gpt_icon":0},{"id":"2581695043","title":"Lunai Bioworks Regains Nasdaq Compliance After Holding Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581695043","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581695043?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:31","pubTimestamp":1762464676,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. announced it had received notice from Nasdaq that it was previously not in compliance with Nasdaq Listing Rule 5620, which requires listed companies to hold an annual meeting of shareholders within one year after the end of their fiscal year. Following the company's annual meeting on October 31, 2025, Nasdaq determined that Lunai Bioworks is now in compliance, and the regulatory matter has been closed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 06, 2025, and is solely responsible for the i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL61RXhJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2581477523","title":"Lunai Bioworks Achieves Complete Regression of Pancreatic Tumors in Preclinical Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2581477523","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581477523?lang=en_us&edition=fundamental","pubTime":"2025-11-05 22:23","pubTimestamp":1762352583,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. has announced a major scientific breakthrough in cancer immunotherapy, reporting that its next-generation allogeneic dendritic cell  therapy led to complete regression of both primary and metastatic pancreatic tumors in preclinical humanized mouse models. The results have already been published in the peer-reviewed journal \"Vaccines\" on November 2, 2025. The study details the development of a second-generation, clinical-grade DC construct, genetically engineered to activate the immune system against cancer. This advancement represents a significant step toward clinical trials and positions Lunai Bioworks at the forefront of next-generation cell-based immunotherapies for pancreatic cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDLbWrr86:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"gpt_icon":0},{"id":"2580225632","title":"Lunai Bioworks Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2580225632","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580225632?lang=en_us&edition=fundamental","pubTime":"2025-11-04 05:32","pubTimestamp":1762205537,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. held its annual shareholder meeting on October 31, 2025. Shareholders voted to elect four directors, approve the appointment of Sadler, Gibb & Associates LLC as the independent registered public accounting firm for the upcoming fiscal year, and approve proposed amendments to the 2023 Equity Incentive Plan. All proposals were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL6fgYTt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"gpt_icon":0},{"id":"2579140689","title":"Lunai Bioworks Unveils AI Platform for Early Detection of Neurotoxic Compounds","url":"https://stock-news.laohu8.com/highlight/detail?id=2579140689","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579140689?lang=en_us&edition=fundamental","pubTime":"2025-10-30 21:32","pubTimestamp":1761831136,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via ACCESS Newswire  on October 30, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL8b3wkz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2579714739","title":"Lunai Bioworks Receives Nasdaq Notice for Market Value Noncompliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2579714739","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579714739?lang=en_us&edition=fundamental","pubTime":"2025-10-30 21:16","pubTimestamp":1761830192,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. has announced that it received a notification from the Nasdaq Stock Market indicating the company is not in compliance with the $35 million minimum Market Value of Listed Securities  requirement. This notice follows 30 consecutive business days during which Lunai Bioworks' MVLS remained below the required threshold. The company has 180 calendar days, until April 27, 2026, to regain compliance by maintaining an MVLS of at least $35 million for a minimum of 10 consecutive business days. Lunai Bioworks' common stock will continue to trade under the symbol \"LNAI\" during this period. If compliance is not regained, the company may face delisting but will have the opportunity to appeal the decision.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDLdgKbK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"gpt_icon":0},{"id":"2575742598","title":"Lunai Bioworks Inc. Announces Landmark Study Identifying Prognostic Biomarkers in Duchenne Muscular Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2575742598","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575742598?lang=en_us&edition=fundamental","pubTime":"2025-10-16 21:45","pubTimestamp":1760622322,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. announced the publication of a new clinical study in Nature Communications, identifying serum protein biomarkers that can predict functional decline in Duchenne Muscular Dystrophy . The study, conducted by a multi-institutional team including Leiden University Medical Center, the University of Florida, and BioSymetrics Inc., analyzed over 700 longitudinal serum samples using the SomaScan proteomics platform. The findings, which have already been presented in the published article, highlight the potential for these biomarkers to inform individual patient trajectories and enhance clinical trial design. BioSymetrics provided analytical support and led the integration of clinical and proteomic data for the project.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDLbNmD3K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RENB","BK4139","LNAI"],"gpt_icon":0},{"id":"2575460741","title":"Lunai Bioworks Regains Nasdaq Compliance with Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2575460741","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575460741?lang=en_us&edition=fundamental","pubTime":"2025-10-16 21:15","pubTimestamp":1760620515,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company had previously received notice from Nasdaq that its common stock had fallen below the required $1.00 minimum bid price for 30 consecutive business days. However, after the stock maintained a closing bid price of at least $1.00 per share for 11 consecutive business days from September 30, 2025, to October 14, 2025, Lunai Bioworks met the requirements and remains eligible for continued listing on The Nasdaq Capital Market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via ACCESS Newswire  on October 16, 2025, and is solely responsible fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL5PdDWl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2575873418","title":"Lunai Bioworks Inc. Announces Date for Upcoming Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2575873418","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575873418?lang=en_us&edition=fundamental","pubTime":"2025-10-16 00:07","pubTimestamp":1760544462,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. will hold its 2025 Annual Meeting of Stockholders on October 31, 2025. During the meeting, stockholders will vote on a non-binding advisory proposal to approve the compensation paid to the company's named executive officers, as disclosed in the company's compensation tables and related materials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL1FwYGP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"gpt_icon":0},{"id":"2573670638","title":"Lunai Bioworks Signs First Commercial Contract for AI-Based Early Alzheimer's Detection Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2573670638","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573670638?lang=en_us&edition=fundamental","pubTime":"2025-10-06 21:16","pubTimestamp":1759756587,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. announced it has signed its first commercial contract in its Alzheimer's disease program. The agreement involves the use of Lunai's AI platform, Augusta, to identify early biomarkers of Alzheimer's disease by integrating MRI, genetic, and metabolic data. The company reports that this technology has achieved up to a 35% improvement in diagnostic accuracy compared to using MRI data alone. The new contract follows Lunai's ongoing collaborations with research institutions and pharmaceutical companies aimed at advancing multi-modal machine learning approaches for neurodegenerative disease diagnostics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this n","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL81ZN8S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"gpt_icon":0},{"id":"2571328051","title":"Lunai Bioworks Announces 10-for-1 Reverse Stock Split, Trades Under New Ticker \"LNAI","url":"https://stock-news.laohu8.com/highlight/detail?id=2571328051","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571328051?lang=en_us&edition=fundamental","pubTime":"2025-09-30 21:15","pubTimestamp":1759238123,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc.  has completed a 10-for-1 reverse stock split, reducing its outstanding shares from approximately 231.8 million to 23.2 million. The move is aimed at enhancing capital efficiency and meeting Nasdaq's minimum bid price requirements, following the company's recent rebranding and strategic focus on AI-powered therapeutics and biodefense.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via ACCESS Newswire  on September 30, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL1PWmGv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LNAI","BK4585","LU2095319765.USD","IE00BGHQF748.EUR","BK4112","RENB","BK4139","LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","NDAQ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.renovarogroup.com","stockEarnings":[{"period":"1week","weight":0.0007},{"period":"1month","weight":-0.2227},{"period":"3month","weight":-0.2468},{"period":"6month","weight":-0.6637},{"period":"1year","weight":-0.8727},{"period":"ytd","weight":0.102}],"compareEarnings":[{"period":"1week","weight":-0.0103},{"period":"1month","weight":-0.0011},{"period":"3month","weight":0.0209},{"period":"6month","weight":0.0925},{"period":"1year","weight":0.1685},{"period":"ytd","weight":0.0018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.041139},{"month":2,"riseRate":0.428571,"avgChangeRate":0.007158},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.077517},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.083247},{"month":5,"riseRate":0.5,"avgChangeRate":-0.0442},{"month":6,"riseRate":0.375,"avgChangeRate":-0.147122},{"month":7,"riseRate":0.625,"avgChangeRate":-0.018947},{"month":8,"riseRate":0.625,"avgChangeRate":0.533577},{"month":9,"riseRate":0.375,"avgChangeRate":-0.022213},{"month":10,"riseRate":0.5,"avgChangeRate":-0.035033},{"month":11,"riseRate":0.75,"avgChangeRate":0.142505},{"month":12,"riseRate":0.375,"avgChangeRate":-0.12056}],"exchange":"NASDAQ","name":"Lunai Bioworks","nameEN":"Lunai Bioworks"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lunai Bioworks(LNAI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lunai Bioworks(LNAI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lunai Bioworks,LNAI,Lunai Bioworks股票,Lunai Bioworks股票老虎,Lunai Bioworks股票老虎国际,Lunai Bioworks行情,Lunai Bioworks股票行情,Lunai Bioworks股价,Lunai Bioworks股市,Lunai Bioworks股票价格,Lunai Bioworks股票交易,Lunai Bioworks股票购买,Lunai Bioworks股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lunai Bioworks(LNAI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lunai Bioworks(LNAI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}